Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2EneEKN
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
Abstract Purpose Currently, intraoperative ultrasound in brain tumor surgery is a rapidly propagating option in imaging technology. We e...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Publication date: Available online 6 November 2017 Source: Academic Radiology Author(s): Steven J. Esses, Samir S. Taneja, Andrew B. Ros...
-
Publication date: Available online 6 January 2018 Source: Current Problems in Diagnostic Radiology Author(s): Mark D. Kovacs, Maximilian...
-
Background Chronic rhinosinusitis (CRS) is a commonly observed sequela after radiation therapy to the paranasal sinuses. The histopatholo...
-
[Intermittent hypoxia due to sleep apnea syndrome in patients with type 2 diabetes mellitus]. Zh Nevrol Psikhiatr Im S S Korsakova. 20...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου